Showing posts with label ICMR. Show all posts
Showing posts with label ICMR. Show all posts
Monday, January 2, 2012

12 MP doctors let off with Rs.5,000 fine for conducting illegal drug trials

0 comments
<-- Drug Trial Victim " Yatharth".

As penalties for subjecting patients to guinea pig treatment go, this one would not even register on the blip screen. 

A dozen government doctors in Indore got a mere slap on the wrist on Saturday evening when they were fined Rs.5,000 for allegedly conducting controversial drug trials on 1,883 poor and unsuspecting hospital inmates, many of whom suffered from side effects and some even lost their lives. 

The trials, that took place over a period of four years in three hospitals, shockingly did not either have the government's permission or the patients' informed consent. What was worse, the accused appeared to have covered their tracks by not furnishing the details of the drugs or vaccines used in the experiments as also the names and particulars of the victims. In these circumstances, assessing the precise extent of damage in terms of side effects and fatalities was an onerous task. 

Instead of looking at the criminal conduct of errant doctors belonging to government hospitals of Indore, the probe conducted by the city's chief medical and health officer (CMHO), Dr Sharad Pandit, merely invoked the Madhya Pradesh Nursing Homes and Clinical Establishment (registration and licence) Amendment Act, 2003, to impose the paltry penalty. The Madhya Pradesh government's disdain for the victims was further laid bare by the untouched provision of the same law that provides for a maximum fine of Rs.50,000. 

Even that amount, however, would not have been a serious deterrent for the doctors who, according to Paras Sacklecha (an Independent legislator from Ratlam), had pocketed Rs.1.44 crore from private pharmaceutical companies to conduct the trials. "They lured poor and illiterate patients without telling them about the implications involved," Sacklecha alleged. It was he who obtained the figure of 1,883 victims, including children and mentally challenged persons, from the government under the RTI Act. 

"In fact, without taking permission for the drug trial from the government, the doctors have not only taken the huge sum from pharma majors but also embarked on foreign tours," Sacklecha added. The penalty, interestingly, was imposed on the doctors for not furnishing the details of the victims who had been subjected to the trials. 

"A fine of Rs.5,000 each has been imposed on 12 doctors of autonomous medical colleges and hospitals attached with them for conducting drug trials on children and mentally challenged persons. The doctors had expressed their inability to provide details of drug or vaccine trial, citing a provision of the Drug and Cosmetics Rules, 1945," medical education department deputy secretary Shyam Singh Kumre said. 

In effect, therefore, action had been taken only for their failing to provide data to the CMHO under the nursing homes Act. Even the press note was silent on the illegality of the doctors' action. It merely talked about new norms: "The state government is serious about the complaints received in this connection and fresh guidelines will be issued after chalking out new parameters."

But Dr Anand Rai, the whistleblower and a government doctor of Dhar district, said: "A maximum fine of Rs.50,000 could be imposed if the nursing homes were not registered or were unable to furnish monthly data. Yet the fine slapped on the doctors was the bare minimum." 

Rai felt the government had simply let off the doctors despite their performing drug trials on patients who had gone to the government hospitals for routine treatment. "Putting such patients under clinical drug trials without taking their consent is a criminal offence," he added.
Between 2006 and 2010, the paediatrics department of MGM Medical College, Chacha Nehru Bal Chikitsalay Avum Anusandhan Kendra, and the department of medicines and neurology of M. Y. Hospital - all Indore- based - allegedly conducted thousands of clinical trials on children, men and women. 

The MP government looked the other way till the issue rocked the state assembly in the last monsoon session, forcing chief minister Shivraj Singh Chouhan to order an enquiry by the Economic Offences Wing. The latter curiously did not come out with the names of the culprit doctors, the beneficiary corporations or even the victims. However, last month, Chouhan claimed that no patient had died during the drug trials in Indore. 

"The state bureau of investigation of economic offences has submitted a chart, along with its report on unethical drug trials, on important facts and statistical data. This chart shows that 81 people had died or fell unwell after the trials. But it has not come to our notice that anyone died directly as a result of the drug trials," the CM told the House, leaving enough room for doubt about whether the home ministry was proficient enough to probe the cause of deaths after the trials. 

Recently, the National Human Rights Commission (NHRC) served a notice to the MP government over reports alleging illegal drug trials on mentally ill patients in Indore. The NHRC asked the state chief secretary to submit a report within four weeks, referring to a media report alleging that 233 mentally ill patients were subjected to drug trials in Indore. 

The NHRC wanted to know whether guidelines of the Indian Council of Medical Research (ICMR) were adhered to by doctors while taking approval for the trials from independent ethics committees attached to private hospitals. It also sought information on whether the nature of the drugs being tested had been revealed. Furthermore, the panel asked whether any survey had been conducted about the status of health of the mentally ill patients who underwent drug trials. 

"Every medicine has some side effects or risks associated with its use. It is very difficult to say what kind of side effects the patients on whom the drugs were tested may have suffered. The most shocking part of the entire Indore drug trial fiasco is that the doctors conducted investigational vaccination trials on illiterate persons without telling them about the implications involved," Dr Anand Rai said.
Read more...
Monday, September 26, 2011

Apollo Hospitals on the hunt for Health Street ally

0 comments
Apollo Hospitals Enterprises is seeking a strategic partner for its information technology-based-solutions subsidiary Apollo Health Street.
The ally is being inducted for strategic reasons, not just capital.
“We are not looking to just raise money by roping in a partner. The partner is going to be for strategic reasons. We can’t give more details at this point,” Prathap C Reddy, Apollo’s chairman, told DNA.
The company was keen on a foreign partner, he said.
Apollo Health Street Ltd develops IT-based solutions for healthcare organisations.
It offers revenue cycle outsourcing, focused outsourcing, third-party, EMS billing, follow-up and private pay, and several such solutions that would primarily help in hospital management.
Apollo Health Street was founded in 1999 and is headquartered in Hyderabad with operations in various locations in India and the US.
Sources have also been talking about a consolidation strategy that is being worked out by Apollo Hospitals.
The strategy, according to sources, was to consolidate the holdings in various hospitals managed by Apollo with an eventual objective of owning the hospitals fully instead of managing the hospitals with joint venture partners.
Refusing to comment on the status of the strategy, Reddy said, “I will not talk about it. Don’t make things expensive for me.”
Meanwhile, Apollo has joined hands with the US-based healthcare and regenerative medicine major Cytori Therapeutics.
As part of the alliance, Apollo would introduce Cytori’s cell regenerative technology for the first time in India.
“Though there are conventional techniques like stem cell from bone marrow, Cytori has developed the technology for separating stem cells from adipose or fat tissue. “This would mark a new beginning of regenerative medicine in India. The technology helps in collecting the adipose tissue and using it for regenerating the spoilt tissue,” Reddy said.
Adipose tissue is the fatty material in a human body and the obese individuals normally get it removed through liposuction techniques. However, the Cytori team now assures that the tissue, which is otherwise removed, can be used for real-time regeneration of tissue.
“Whether it is for cosmetic reasons to uplift someone’s face or any other body parts or even to treat the damaged body parts including those de-shaped due to radiation necrosis, the adipose tissue can be effectively used. We are still conducting trials on using the technique in curing heart attacks. Unlike in other stem cell techniques, where it needs a culture for about 45 days, the adipose tissue can be immediately used for cell regeneration,” a senior Cytori official said.
Apollo and Cytori are also working on expanding their relationship to conducting clinical trials on the technique in curing ailments like myocardial infraction. “We are yet to get the approvals. We will approach the Indian Council of Medical Research (ICMR) for going ahead with the trials,” Reddy said.
Apollo is likely to offer cosmetic and medical application of the Cytori’s regenerative therapy for about `1 lakh. However, Cytori is also planning to tie up with more healthcare institutions in India for offering the technology apart from tying up with medical equipment manufacturers to manufacture some of the consumables in India.
“Once we get the scale, then the consumables would be made here,” the Cytori official said.
Read more...
Wednesday, July 27, 2011

CHAOS IN CLINICAL RESEARCH

0 comments
The recent irregularities reported in conducting of clinical trials by Axis Clinicals, a Hyderabad based CRO, in Andhra Pradesh has once again brought to focus the questionable ways in which clinical trials are being done in India by the pharmaceutical companies and their agents. The report said that the CRO conducted bio-equivalence studies for an anti cancer drug on poor women early this year without securing their informed consent. The episode came to light only last month when some women belonging to this group complained of severe body ache, joint and chest pain and extreme weakness after taking the drug. A few of them even had difficulty in walking. The office of the DCGI raided the premises of the CRO after report came in the media and suspended its license. Axis also will be disallowed from conducting all bio-availability and bio-equivalence studies at their centre for some time now. Investigation carried out by the DCGI officials found irregularities in procedures such as recruitments of subjects and in taking their informed consents. The DCGI also found that the ethics committee at the centre was not functioning independently as required under the existing ICMR guidelines. Many such violations by CROs while conducting clinical trials in India were reported in the recent past and actions were taken against the offenders. But, these offences keep occurring in various parts of the country and very few of them get reported in the media.

After the action taken against the Hyderabad CRO, the office of the DCGI decided to audit all CROs in the country to ensure that the bio-availability and bio-equivalence studies are performed strictly in accordance with the regulatory provisions and prescribed guidelines. The DCGI office has already completed auditing of CROs in Andhra Pradesh and Mumbai. The basic problem with the clinical research in the country is that the sector is not at all effectively regulated. The health ministry has been working for last ten years to put in place a set of comprehensive rules to regulate clinical research with huge flow of contract research jobs into the country. But that has not happened yet. Ethics Committees at most of the trial sites are not active with no monitoring of the trials. What the country has a set of guidelines after amendment of the Schedule Y of Drugs & Cosmetics Act and it is not yet notified. That is what emboldens the MNCs and CROs to conduct trials as they do it now. Now in the case of CROs, a set of draft rules for their mandatory registration was issued by the DCGI some time in July 2009 after it was approved by the Drug Technical Advisory Board. But the registration process is still not in place. The move to make registration mandatory for CROs was taken after finding a spate of irregularities in conducting trials in the past. In short, the slow decision making process in the health ministry is the prime reason for the whole chaos in clinical research front. The matter has to be taken up by the health minister seriously and urgently if this critical sector of the pharmaceutical industry has to function with some order.
Read more...
Wednesday, May 25, 2011

Delhi HC allows use of human placental extract for 2 indications

2 comments

The Delhi High Court has asked the union health ministry to allow the use of human placental extracts for two indications in the country. The two indications include topical application for wound healing and injectibles for pelvic inflammatory diseases.

Accordingly, the ministry will soon amend its notification dated February 10 this year in which it had banned several controversial drugs including human placental extract following the Drugs Technical Advisory Board (DTAB)'s recommendation to the ministry. Other controversial drugs banned by the ministry on February 10 included non-steroid anti-inflammatory drug nimesulide suspension, gastroprokinetic agent cisapride and decongestant drug Phenylpropanolamine (PPA).

After examining the reports submitted by the 9-member expert committee, which went into the issue of efficacy and safety data of human placental extract, the court ordered that human placental extracts should be allowed for two indications. In India, human placenta extract sold as Placentrex lotion, gel and injection is being actively promoted as a remedy for a variety of unrelated disorders such as vitiligo, wound dressing, prevention of adverse effects due to radiotherapy, fallopian tube blockage, female infertility, scarring, post-phlebitic ulcers, scars due to acne, etc.

Earlier on April 6 this year, hearing a petition by the Kolkatta-based pharma company Albert David Ltd, which was a pioneer in human placental extract therapy in the country, the Delhi High Court had asked the union health ministry to constitute an expert panel to go into the issue.

As per the high court order, the government constituted a 9-member expert panel headed by renowned pharmacologist Dr YK Gupta of AIIMS. Other members of the committee included Dr Ajay Kumar of IMA, Dr Vijay Kumar of IDRI, Dr Sharma of ICMR, Dr Kotwal of AIIMS, Dr VK Tiwari, Dr VK Chakravorthy, Dr CM Sharma and Dr Lakhbir Dhaliwal of PGI, Chandigarh.

The committee was asked to submit a report on the matter by May 15 this year. After examining the drug in detail, the panel submitted its report to the court.

Human Placenta extract was never permitted for use as medicine in the western countries such as US, UK, Australia, Canada and European Union states due to lack of efficacy and safety data. However, some companies in US were importing products containing human placenta as dietary supplements. However, on April 14, 2008, all products containing human placenta extracts even for use as cosmetics have been banned by the US government.
Read more...
Sunday, May 15, 2011

ICMR looks for partners to commercialise herbal composition to treat filariasis

0 comments
Indian Council of Medical Research (ICMR) has started scouting for partners to commercialise a novel herbal composition for treatment and prevention of filariasis and an immunodiagnostic reagent for detection of plasmodium vivax in patient’s blood.

Both the products had been developed by the institutes under the ICMR and were now up for grabs by the industry for commercialisation and further research, sources said. Studies were carried out to identify a lead for the development of potent macrofilaricidal from Trachyspermum ammi (Apiaceae family).

“It is an erect branched annual plant up to 90 cm tall, cultivated almost throughout India.  A fruit extract of T.ammi containing monoterpene derivatives has shown effective macrofilaricidal activity both in vivo and in vitro for which toxicological studies are going on. An Indian patent has been filed. The compositions would be effective against short-term as well as long-term treatment and/or prevention of filiraisis caused by Wucheria bancrofti, Brugia malayi, Loa loa and Setaria digitata,” sources said.

Filariasis is a vector borne parasitic disease affecting millions of individuals and is the second leading cause of permanent and long-term disability in the world causing illness ranging from lymphatic inflammation and elephantiasis to skin disease and blindness.

The diagnostic reagent, the second product, is based on immunodiagnostic antibody probe for detection of P. vivax antigen. “Hybridoma cell line has been established for the production of monoclonal antibodies specific to Plasmodium vivax. Monoclonal antibody herein obtained, can be employed for the purpose of immunodiagnostic as an antibody probe for the detection of P. vivax antigen in malaria patient’s blood,” according to the official sources.

“This antigen is non-secretory type, since the monoclonal antibody did not react with plasma. The monoclonal antibody did not show any cross-reactivity with P. falciparum when tested by ELISA and on a western blot, establishing high specificity towards non-secretory antigens of P. vivax. An Indian patent has been filed,” sources added.

The parasite P. vivax is the most frequent and widely distributed cause of malaria. It is one of the four species of parasite, which commonly causes malaria infection in human. P. vivax can reproduce both asexually and sexually, depending on its life cycle stage.
Read more...
Monday, May 9, 2011

ICMR improving quality of project audits for timely, tangible results

0 comments
 The Indian Council of Medical Research (ICMR) is further equipping the existing system to improve the quality in auditing of on-going intramural projects with a view to ensuring timely and tangible results of the projects taken up under its different institutes.

As part of a three-tier system in place for auditing, a scientific advisory committee (SAC), comprising of subject related experts, assists each ICMR Institute and the centre.  The SAC oversees the research activities including review of on-going projects and clearing new project.

The ICMR now is adding new parameters to improve the quality of auditing like assessment of promising leads and ensuring of basic translational research at the institute levels. The ICMR is also seeking further technical and financial resources for the SAC.

There is also a Scientific Advisory Board (SAB) comprising 21 members representing different institutions and disciplines, as specified in the Rules and Regulations of the ICMR, to review the reports. It also recommends advisory groups and offers advices to the ICMR.

The recent meeting of the SAC reviewed the progress made in developing a vaccine against AIDS among other projects recently. “A phase I HIV vaccine trial using the prime boost approach was initiated in NARI, Pune and TRC, Chennai. The enrolment for the trial has been completed and the volunteers are now being followed,” sources said.

New proposal on “ICMR- Indian National Diabetes Study-Phase I,” has been initiated at three states and one Union Territory with the aim to understand prevalence of diabetes and pre-diabetes along its association with the genetic aspects, the meeting was told.

Guidelines on Management of buccal mucosa and cervical cancer have been finalised. As part of a  multi-centric Management of Acute Coronary Event Registry project, a web-based questionnaire had been designed and is currently being validated by entering data from patients registered by MACE registries at different centres.
Read more...
Saturday, April 23, 2011

‘Centre will await ICMR report on endosulfan'

0 comments
Prime Minister Manmohan Singh on Friday assured an all-party delegation from Kerala, led by its Health and Social Welfare Minister P.K. Sreemathy, that the Centre would await the report of the Indian Council for Medical Research (ICMR) before deciding further on the request to ban Endosulfan nationwide.

He reminded the delegates that the Kerala government had already banned the pesticide in 2005. Dr. Singh said during his next visit to Kerala, he would visit Kasaragod district to see and interact with the victims suspected to be affected by the use of the pesticide in cashew plantations.

Meanwhile, Union Minister of State for Environment and Forests Jairam Ramesh said that Endosulfan would be banned if its adverse effect on health was proved.

“If there is evidence to show that it has all-India health effects, we will ban it at the national level.” However Mr. Ramesh claimed that Endosulfan was a broad spectrum pesticide and there were no other cost-effective alternatives to it as yet. He knew about the disaster in Kasaragod and had asked for more evidence. “Some people say there are other districts in Karnataka, which have also been affected. I am very sensitive to this issue,” he said.

Ms. Sreemathy, justifying the need for banning Endosulfan at the all-India level, told journalists that the delegation pointed out to the Prime Minister that there was enough evidence from the experience of Kasaragod to prove that the pesticide would cause irreparable damage to the environment and human beings exposed to it. An earlier study of the ICMR had proved this and “we strongly believe that there is no need for dragging on the matter in the name of further study.”

Eighty-one countries had either banned Endosulfan or decided to phase out its use. The delegation wanted Dr. Singh to give appropriate instructions so that India took a strong stand against Endosulfan and sought its ban during the April 25 discussion on Stockholm convention on the use of persistent organic pollutants to be held in Geneva.

“During the last round of discussions, India had taken a stand against the ban on Endosulfan, which had caused widespread anger and criticism in India, especially among victims in Kerala who are fighting for their rights and rehabilitation,” she said.

The 13-member delegation comprised Kerala Water Resources Minister N.K. Premachandran, Devaswom Minister Kadannapally Ramachandran, Forests and Housing Minister Benoy Viswom and Transport Minister Jose Thettayil; C.T. Ahamed Ali and A.K. Saseendran (IUML); Thalekunnil Basheer (Congress); P.C. Thomas (Kerala Congress-AMG); V. Muraleedharan (BJP), Joy Abraham (Kerala Congress M), A.N. Rajan Babu (JSS) and Dr. Varghese George (Socialist Janata (Democratic). LDF MPs from Kerala will stage a dharna in Parliament complex on April 26 seeking a ban on Endosulfan and later present a memorandum to Dr. Singh.
Read more...
 
Clinical Research News © 2012 crtnews.co.cc. Supported by Sai Clinical Services